Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 801–900 of 1,448
Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases
Rickenbach, C., & Gericke, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.806260 · Cited by 37
Yoon, I., Pietrzik, C. U., Kang, D. E., & Koo, E. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413729200 · Cited by 38
Mahaman, Y. A. R., Feng, J., Huang, F., Salissou, M. T. M., Wang, J., Liu, R., Zhang, B., Li, H., Zhu, F., & Wang, X. (2022) · Nutrients · doi:10.3390/nu14204284 · Cited by 37
Morrone, C. D., Liu, M., Black, S. E., & McLaurin, J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00064 · Cited by 26
“Furthermore, in AD patients and a mouse model of cerebrovascular amyloid angiopathy (CAA), LRP-1 staining is greatly reduced on vessels and is co-localized to amyloid plaques (Shibata et al., 2000; Deanne et al., 2004; Donahue et al., 2006).”
BackgroundRationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy
Ghochikyan, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787847298 · Cited by 33
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript APP Amyloid precursor protein BBB Blood brain barrier CAA Cerebral amyloid angiopathy CSF Cerebral spinal fluid CTF C-terminal fragment LRP Lipoprotein receptor-related protein 1 MAP Multiple antigenic peptide MDC Macrophage derived ch…”
BackgroundThal, D. R. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.72 · Cited by 32
“560 Alterations of the perivascular drainage of Aβ are found in AD as indicated by the findings that (1) Aβ is cleared through the perivascular space[1] in addition to its cellular uptake and degradation[4,6,8,30], and its clearance across the capillary BBB segment[25,31,32]; (2) cerebral amyloid”
BackgroundADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology
Cao, Y., Xu, H., Zhu, Y., Shi, M.-J., Wei, L., Zhang, J., Cheng, S., Shi, Y., Tong, H., Kang, L., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000313 · Cited by 31
RetractedPeripheral proteinopathy in neurodegenerative diseases
Xu, B., Lei, X., Yang, Y., Yu, J., Chen, J., Xu, Z., Ye, K., & Zhang, J. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-024-00461-6 · Cited by 37
Tzekaki, E. E., Papaspyropoulos, A., Tsolaki, M., Lazarou, E., Kozori, M., & Pantazaki, Α. A. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111178 · Cited by 36
The Blood-Brain Barrier in Alzheimer’s Disease
Storck, S. E., Hartz, A. M. S., & Pietrzik, C. U. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_418 · Cited by 32
Yamada, S. (2021) · Croatian Medical Journal · doi:10.3325/cmj.2021.62.399 · Cited by 31
Sharp, F. R., DeCarli, C. S., Jin, L., & Zhan, X. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1096206 · Cited by 37
“Low-density lipoprotein receptor-related protein 1 is the main transporter for Abeta out of cells and out of brain via the BBB (Shibata et al., 2000; Zlokovic et al., 2010).”
BackgroundA Role for Hemopexin in Oligodendrocyte Differentiation and Myelin Formation
Morello, N., Bianchi, F. T., Marmiroli, P., Tonoli, E., Menendez, V. R., Silengo, L., Cavaletti, G., Vercelli, A., Altruda, F., & Tolosano, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020173 · Cited by 33
“In addition, both Hx and MMPs are cleared from the extracellular environment by low-density lipoprotein receptor-related protein-1 (LRP-1) [32,33], a scavenger receptor expressed in CNS by epithelial cells of choroid plexi, endothelial cells of microvessels, neurons, perivascular astrocytes, and microglial cells [34,3…”
BackgroundRegulation of β-amyloid level in the brain of rats with cerebrovascular hypoperfusion
Liu, H., Xing, A., Wang, X., Liu, G., & Li, L. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.027 · Cited by 38
Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer’s Disease?1
Kuhn, A. J., & Raskatov, J. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191201 · Cited by 39
Ali, M., Saleem, U., Anwar, F., Imran, M., Nadeem, H., Ahmad, B., Ali, T., Atta-ur-Rehman, & Ismail, T. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03229-w · Cited by 33
Prevention of age-associated dementia
Mohajeri, M. H., & Leuba, G. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.06.014 · Cited by 37
“Other than by mediating microglial uptake of A , anti-A antibodies may also clear A from the CNS by inducing a shift in the equilibrium between the two compartments and facilitate A flux from a central compartment to a periphery [30,140].”
BackgroundOu-Yang, M.-H., & Van Nostrand, W. E. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-134 · Cited by 30
“Efflux of Aβ into plasma or CSF is unaltered in Tg-5xFAD/ MBP mice Efflux into plasma or CSF represents major clearance pathways for Aβ in brain [47-49].”
BackgroundProtection of the Blood-Brain Barrier by Pentosan Against Amyloid-β-Induced Toxicity
Deli, M. A., Veszelka, S., Csiszár, B., Tóth, A. E., Kittel, Á., Csete, M., Sipos, Á., Szalai, A., Fülöp, L., Penke, B., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100759 · Cited by 33
The role of lipoprotein receptors on the physiological function of APP
Wagner, T., & Pietrzik, C. U. (2011) · Experimental Brain Research · doi:10.1007/s00221-011-2876-8 · Cited by 33
Development of a Multicomponent Intervention to Prevent Alzheimer's Disease
Saitô, S., Yamamoto, Y., & Ihara, M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00490 · Cited by 31
“Endothelial low-density lipoprotein receptor related protein-1 (LRP-1), a multifunctional scavenger and signaling receptor, is expressed in neural cells and cerebral microvessels (49, 53).”
BackgroundFalsetti, L., Viticchi, G., Zaccone, V., Guerrieri, E., Moroncini, G., Luzzi, S., & Silvestrini, M. (2022) · Biomedicines · doi:10.3390/biomedicines10020439 · Cited by 34
“Total cholesterol serum levels appear to be independently associated with increased AD prevalence, with a potential modulation of the effect by ApoE genotype [101].”
BackgroundInfluentialModulations of bioactive lipids and their receptors in postmortem Alzheimer’s disease brains
Kurano, M., Saito, Y., Uranbileg, B., Saigusa, D., Kano, K., Aoki, J., & Yatomi, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1066578 · Cited by 33
“ApoE-rich HDL binds to LDL receptor and LRP1, which have been also demonstrated to be involved in the pathogenesis of AD (Shibata et al., 2000; Deane et al., 2004; Shi et al., 2021).”
BackgroundChristoforidis, M., Schober, R., & Krohn, K. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2004.00614.x · Cited by 30
Alzheimer's dementia by circulation disorders: when trees hide the forest
Dotti, C. G., & Strooper, B. D. (2009) · Nature Cell Biology · doi:10.1038/ncb0209-114 · Cited by 30
Wu, C., Lin, T., Ding, Q., Zhang, N., Ou, Z.-T., Cai, G., Chen, H., Xu, J.-Y., Li, G., Pei, Z., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/2140524 · Cited by 33
“Blood-brain barrier mediates Aβ clearance through several receptors and transporters, such as the low-density lipoprotein receptor-related protein 1 (LRP1), P-glycoprotein (P-gp), and the receptor for advanced glycation end products (RAGE) [6, 7].”
BackgroundGulej, R., Patai, R., Ungvari, A., Kállai, A., Tarantini, S., Yabluchanskiy, A., Huffman, D. M., Conboy, M. J., Conboy, I. M., Kivimäki, M., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01657-y · Cited by 32
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys
Noveir, S. D., Kerman, B. E., Xian, H., Meuret, C. J., Smadi, S., Martinez, A. E., Johansson, J., Zetterberg, H., Parks, B. A., Kuklenyik, Z., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01028-1 · Cited by 30
“This aligns with the present study’s finding that CS-6253 was able to simultaneously increase Aβ42 concentrations in plasma and decrease them in CSF. Studies have shown support for this hypothesis, showing that increasing peripheral Aβ antibodies and Aβ-binding lipoproteins increase Aβ efflux [8, 42] through LRP1 [43,…”
BackgroundInfluentialKisler, K., Sagare, A. P., Lazić, D., Bazzi, S. A., Lawson, E. J., Hsu, C.-J., Wang, Y., Ramanathan, A., Nelson, A. R., Zhao, Z., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00597-5 · Cited by 35
Darlington, D., Li, S., Hou, H., Habib, A., Tian, J., Gao, Y., Ehrhart, J. C., Sanberg, P. R., Sawmiller, D. R., Giunta, B. N., et al. (2015) · Cell Transplantation · doi:10.3727/096368915x688894 · Cited by 42
“The binding of Ab to receptors that can mediate its clearance has therefore been a major therapeutic focus (10,24,35,41,43).”
Mohamed, L. A., & Kaddoumi, A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052514 · Cited by 32
Dendrimer-based magnetic resonance imaging agents for brain cancer
Ding, L., Lyu, Z., Dhumal, D. M., Kao, C., Bernard, M., & Peng, L. (2018) · Science China Materials · doi:10.1007/s40843-018-9323-6 · Cited by 32
The Blood–Brain Barrier: Much More Than a Selective Access to the Brain
Sánchez-Cano, F., Hernández‐Kelly, L. C., & Ortega, A. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00431-0 · Cited by 35
Mechanisms of Aβ Clearance and Catabolism
Guénette, S. Y. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:3:147 · Cited by 34
“Furthermore, it is now known that rapid sequestration of Aβ40 across the blood–brain barrier into the brain vasculature occurs via an active transport mechanism (see section on Aβ Clearance) (Shibata et al., 2000).”
BackgroundInfluentialPritchard, A. L., Harris, J. M., Pritchard, C. W., Clair, D. S., Lemmon, H. A., Lambert, J., Chartier‐Harlin, M., Hayes, A., Thaker, U., Iwatsubo, T., et al. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.016 · Cited by 29
Cerebrovascular Pathology in Hypertriglyceridemic APOB-100 Transgenic Mice
Hoyk, Z., Tóth, M. E., Lénárt, N., Nagy, D., Dukay, B., Csefová, A., Zvara, Á., Seprényi, G., Kincses, A., Walter, F. R., et al. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00380 · Cited by 29
“Additionally, the receptors Lrp1, Lrp2 and the transporter P-gp responsible for the clearance of Aβ from the brain (Shibata et al., 2000; Deane et al., 2003; Cirrito et al., 2005) are downregulated in AD pathology (Marques et al., 2013).”
BackgroundMuza, P. M., Bachmeier, C. J., Mouzon, B., Algamal, M., Rafi, N. G., Lungmus, C., Abdullah, L. I., Evans, J. E., Ferguson, S., MULLAN, M. J., et al. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.01.049 · Cited by 33
Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?
Menéndez‐González, M., & Gasparovic, C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01036 · Cited by 29
“Though the relationship between plasma and ISF levels is still not fully understood, in AD the Aβ transporter LRP1 on the abluminal side of the capillary endothelium has been reported to be reduced in number (41, 59) while the Aβ transporter receptor for advanced glycation end products (RAGE) on the luminal side of mi…”
BackgroundHow does the brain remove its waste metabolites from within?
Cheng, Y., & Haorah, J. (2019) · PubMed Central · Cited by 37
Targeting the Choroid Plexuses for Protein Drug Delivery
Bryniarski, M. A., Ren, T., Rizvi, A. R., Snyder, A. M., & Morris, M. E. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100963 · Cited by 29
Impact of the Cannabinoid System in Alzheimer's Disease
Li, S., Huang, Y., Yu, L., Ji, X., & Wu, J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220201091006 · Cited by 28
Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?
von Bernhardi, R. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1248 · Cited by 28
“…a net efflux of A β from the brain to plasma [49,121,122],a mechanism that is present in normal animals [123] and appears to be mediated by the interaction between lipoprotein receptor-related protein (LRP) and A β at the brain capillary, and also becomes compromised in aging and in AD [124].”
Clearance of amyloid β-protein and its role in the spreading of Alzheimer's disease pathology
Thal, D. R. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00025 · Cited by 29
“…R. Thal, dietmar.thal@uni-ulm.de Received: 26 January 2015 Paper pending published: 17 February 2015 Accepted: 22 February 2015 Published: 09 March 2015 Citation: Thal DR (2015) Clearance of amyloid β-protein and its role in the spreading of Alzheimer’s disease pathology Front.”
A Toxic Conformer of Aβ42 with a Turn at 22–23 is a Novel Therapeutic Target for Alzheimer’s Disease
Izuo, N., Kasahara, C., Murakami, K., Kume, T., Maeda, M., Irie, K., Yokote, K., & Shimizu, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-11671-6 · Cited by 31
Alcohol promotes waste clearance in the CNS via brain vascular reactivity
Cheng, Y., Liu, X., Ma, X., García, R. J. B., Belfield, K. D., & Haorah, J. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.07.029 · Cited by 30
Dabbs, R. A., Wyatt, A. R., Yerbury, J. J., Ecroyd, H. W., & Wilson, M. R. (2011) · Topics in current chemistry · doi:10.1007/128_2011_262 · Cited by 29
Human α2-macroglobulin: genotype–phenotype relation
Birkenmeier, G., Müller, R., Huse, K., Forberg, J., Gläser, C., Hedrich, H., Nicklisch, S., & Reichenbach, A. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00110-9 · Cited by 28
Can statins put the brakes on Alzheimer’s disease?
Whitfield, J. F. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.12.1479 · Cited by 32
Li, W., Chen, C., Xu, B., Chen, J., Yang, M., Gao, L., & Zhou, J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116643 · Cited by 29
Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment
Stowe, A. M., Ireland, S. J., Ortega, S. B., Chen, D., Huebinger, R. M., Tarumi, T., Harris, T. S., Cullum, C. M., Rosenberg, R. N., Monson, N. L., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0910-x · Cited by 42
Fan, Y., Guo, T., Han, X., Liu, J.-L., Cai, Y.-T., Han, X., Huang, X., Li, Y., Wang, Z., & Guo, C. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.014 · Cited by 28
McCarty, M. F., DiNicolantonio, J. J., & Lerner, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042140 · Cited by 29
Effect of β-amyloid on blood-brain barrier properties and function
Petrushanko, I. Y., Mitkevich, V. A., & Makarov, A. А. (2023) · Biophysical Reviews · doi:10.1007/s12551-023-01052-x · Cited by 29
“During Alzheimer’s disease, there is an increase in the transport of Aβ from the blood to the brain due to an increase in RAGE level and a decrease in LRP1 level.”
BackgroundInfluentialSome aspects of astroglial functions and aluminum implications for neurodegeneration
Aremu, D. A., & Meshitsuka, S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.02.001 · Cited by 29
“There is accumulated evidence that factors regulating Aβ catabolism (Carson and Turner, 2002; Iwata et al., 2000), clearance (Morelli et al., 2002; Shibata et al., 2000), and aggregation (Wisniewski et al., 1997; Wolozin, 2004) are critical in regulating its metabolism.”
BackgroundAlzheimer’s Silent Partner: Cerebral Amyloid Angiopathy
Cupino, T. L., & Zabel, M. K. (2013) · Translational Stroke Research · doi:10.1007/s12975-013-0309-7 · Cited by 32
“Bulk flow and perivascular drainage are very slow [70] and only responsible for about 10–15 % of Aβ clearance, while the majority is transcytosed across the blood–brain barrier [71].”
Amylin Enhances Amyloid-β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier
Mohamed, L. A., Zhu, H., Mousa, Y. M., Wang, E., Qiu, W. Q., & Kaddoumi, A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160800 · Cited by 28
“LRP1 is localized to the brain side of the BBB; it is involved in facilitating A (cid:2) uptake and subsequent efflux across the BBB [35, 45].”
Ringland, C., Schweig, J. E., Paris, D., Shackleton, B., Lynch, C., Eisenbaum, M., MULLAN, M. J., Crawford, F., Abdullah, L. I., & Bachmeier, C. J. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.018 · Cited by 31
“…elimination route of Aβ from the brain is transport via the low-density lipoprotein receptor (LDLR) and the LDLR-related protein-1 (LRP1) receptors, which have been shown to be dysregulated in AD (Bell et al., 2007; Deane et al., 2008; Kanekiyo et al., 2014; Shibata et al., 2000; Zlokovic, 2005).”
BackgroundChapter 7 Cell Protective Functions of Secretory Clusterin (sCLU)
Klock, G., Baiersdörfer, M., & Koch-Brandt, C. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)04007-x · Cited by 33
“While the influx of A across the BBB into the brain is mediated by direct binding of A to the receptor for advanced glycation end products (RAGE), lipoprotein receptors have been suggested to facilitate the clearance of A from the brain into the blood by transcytosis (Bell et al., 2007; Shibata et al., 2000; Zlokovic,…”
BackgroundZannis, V. I., Κούκος, Γ., Drosatos, K., Vezeridis, A. M., Zanni, E. E., Kypreos, K. E., & Chroni, A. (2008) · Annals of Medicine · doi:10.1080/07853890701687219 · Cited by 31
de Oliveira, J., Moreira, E. L. G., & Bem, A. F. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102149 · Cited by 27
Kelliny, S., Zhou, X., & Bobrovskaya, L. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70046 · Cited by 31
“The other main route of Aβ clearance from the brain is believed to occur through direct trafficking out of the brain via LDL receptor–re-lated protein-1 (LRP-1) and P-glycoprotein (Shibata et al. 2000) at the BBB into peripheral circulation, through which 40%–60% of brain Aβ is cleared mainly through the liver and kid…”
Pan, X., Zz, L., Gg, J., Lp, W., Cm, B., Yl, W., Chen, M. F., & Li, W. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105417 · Cited by 32
Tolstova, A. P., Adzhubei, A. A., Mitkevich, V. A., Petrushanko, I. Y., & Makarov, A. А. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911816 · Cited by 27
“The BBB controls the uptake of Aβ from plasma to the brain via the multi-ligand Advanced glycosylation end product-specific receptor (RAGE) [4,5], and the removal of the brain-derived Aβ via the LRP1 receptor [6,7].”
BackgroundAshby, E. L., Miners, J. S., Kumar, S., Walter, J., Love, S., & Kehoe, P. G. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12212 · Cited by 29
Self-citationThe p75NTR extracellular domain
Zhou, X., & Wang, Y. (2011) · Prion · doi:10.4161/pri.5.3.16896 · Cited by 26
Chen, F., Ghosh, A., Hu, M. Y., Long, Y., Sun, H., Kong, L., Hong, H., & Tang, S. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9784-z · Cited by 26
“…the lumina of the endothelial cytoplasm of the BBB, is involved in the receptor mediated amyloid-β (Aβ) trafficking across the BBB (Deane et al. 2004a, 2004b; Wan et al. 2015; Zhang and Lee 2011), and is critical for maintaining Aβ homeostasis in the brain (Deane et al. 2003; Shibata et al. 2000).”
BackgroundOkuyama, H., Hamazaki, T., Hama, R., Ogushi, Y., Kobayashi, T., Ohara, N., & Uchino, H. (2018) · Pharmacology · doi:10.1159/000486374 · Cited by 28
Traumatic Brain Injury, Chronic Traumatic Encephalopathy, and Alzheimer Disease
Al‐Dahhak, R., Khoury, R., Qazi, E., & Grossberg, G. T. (2018) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2018.06.008 · Cited by 27
Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET
Zoufal, V., Wanek, T., Krohn, M., Mairinger, S., Filip, T., Sauberer, M., Stanek, J., Pekar, T., Bauer, M., Pahnke, J., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18806640 · Cited by 27
“membrane, the low-density lipoprotein receptor-related protein 1 (LRP1) was shown to be responsible for Ab transfer from brain parenchyma into capillary endothelial cells.(5,6) There is accumulating evidence that Ab efflux across the luminal endothelial membrane of the BBB into the blood is mediated by the adenosine t…”
BackgroundAmyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies
Dileep, K. V., & Chandra, R. (2019) · Current Drug Targets · doi:10.2174/1389450120666190806153206 · Cited by 27
Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice
Abdallah, I. M., Al-Shami, K. M., Yang, E., & Kaddoumi, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031231 · Cited by 27
“Efflux transporters P-glycoprotein (P-gp, ABCB1), breast cancer resistant protein (BCRP, ABCG2), and low-density lipoprotein receptor-related protein-1 (LRP-1) regulate the traffic across the BBB to the blood and play key roles in brain Aβ homeostasis [14,15].”
BackgroundEffects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins
Banks, W. A., Pagliari, P., Nakaoke, R., & Morley, J. E. (2004) · Peptides · doi:10.1016/j.peptides.2004.09.016 · Cited by 28
Hao, J., Zhang, W., Zhang, P., Liu, R., Liu, L., Lei, G., Su, C., Miao, J., & Li, Z. (2010) · Neuropeptides · doi:10.1016/j.npep.2010.03.001 · Cited by 27
“Although the role of apoE in the pathogenesis of AD is not well understood so far, increasing evidence has shown that apoE binds Ab with high affinity by direct protein-toprotein interaction and acts as a ‘‘double-edged sword” in the pathogenesis of AD, being involved in the Ab clearance through the blood–brain barrie…”
Vargas-Rodríguez, P., Cuenca-Martagón, A., Castillo-González, J., Serrano-Martínez, I., Luque, R. M., Delgado, M., & González-Rey, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814117 · Cited by 25
Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
Engelhardt, E., Resende, E. D. P. F., & Gomes, K. B. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-vr01 · Cited by 25
Microglia internalize tau monomers and fibrils using distinct receptors but similar mechanisms
Falkon, K. F., Danford, L., Kuri, E. G., Esquinca‐Moreno, P., Señeriz, Y. L. P., Smith, S. A., Wickline, J. L., Louwrier, A., McPhail, J. A., Sayre, N. L., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14418 · Cited by 26
“17 It should be stated that HSPGs and LRP1 also mediate the internalization of a multitude of other ligands, including amyloid beta (A β ) 18,19 and apolipoprotein E. 20–22 Astrocytes internalize tau via an integrinreceptorcomplex 23 andHSPGs 24…”
Impaired autophagy in amyloid-beta pathology: A traditional review of recent Alzheimer's research
Yuan, M., Wang, Y., Huang, Z., Jing, F., Qiao, P., Zou, Q., Li, J., & Cai, Z. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20220145 · Cited by 27
“Neprilysin, a type II metalloproteinase, is responsible for extracellular degradation of Aβ42, and its activation can reduce the aggregation and toxicity related to Aβ, leading potentially to cognitive improvements[58,62].”
BackgroundVerma, N., Velmurugan, G. V., Winford, E. D., Ly, H., Kotiya, D., Leibold, N. S., Radulescu, L., Despa, S. I., Chen, K. C., Eldik, L. J. V., et al. (2023) · Communications Biology · doi:10.1038/s42003-022-04398-2 · Cited by 30
Ruzali, W. A. W., Kehoe, P. G., & Love, S. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.07.065 · Cited by 26
Silverberg, G. D., Miller, M. C., Pascale, C. L., Caralopoulos, I. N., Ağca, Y., Agca, C., & Stopa, E. G. (2015) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-12-2 · Cited by 29
“Clearance of macromolecules, such as Aβ, from the brain interstitial space involves at least four different pathways: i) via in situ degradation [26-30], ii) active transport across the blood–brain barrier [31-36], iii) across the choroid plexus epithelium by active transport [37], and iv) via the production and turno…”
BackgroundTREM1: A Potential Therapeutic Target For Alzheimer’s Disease
Saadipour, K. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9716-y · Cited by 27
“2003) and low-density lipoprotein receptor-related protein-1 (LRP1) (Shibata et al. 2000) contribute to Aβ transportation across the blood brain barrier (BBB) from the systemic circulation into the brain and vice versa, respectively.”
InfluentialFimognari, N., Hollings, A. L., Lam, V., Tidy, R. J., Kewish, C. M., Albrecht, M. A., Takechi, R., Mamo, J. C. L., & Hackett, M. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00193 · Cited by 26
Yang, H., Wang, W., Jia, L., Qin, W., Hou, T., Wu, Q., Li, H., Tian, Y., & Jia, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191045 · Cited by 27
Grimwood, S., Hogg, J. E., Jay, M. T., Lad, A. M., Lee, V. S., Murray, F., Peachey, J., Townend, T., Vithlani, M., Beher, D., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.01.016 · Cited by 25
Effects of medications on plasma amyloid beta (Aβ) 42: Longitudinal data from the VITA cohort
Blasko, I., Jungwirth, S., Jellinger, K. A., Kemmler, G., Krampla, W. W., Weissgram, S., Wichart, I., Tragl, K. H., Hinterhuber, H., & Fischer, P. A. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.10.010 · Cited by 25
“Assuming that significant amount of Ab42 peptides is delivered throughout the blood brain barrier to plasma circulation, measurement of these changes might be of importance (Shibata et al., 2000).”
BackgroundTetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease
Corino, C., Aimo, A., Luigetti, M., Ciccone, L., Chen, Y. F. F., Panichella, G., Musetti, V., Castiglione, V., Vergaro, G., Emdin, M., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04442-8 · Cited by 28
Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer’s Disease
Nelson, A. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.858429 · Cited by 25
“RAGE is normally expressed at low levels at the BBB, but its expression is increased in normal aging and in AD brain endothelium and is associated with increased cerebrovascular and brain accumulation of Aβ (Yan et al., 1996; Silverberg et al., 2010; Deane et al., 2012).”
BackgroundIn vitro and in vivo degradation of Aβ peptide by peptidases coupled to erythrocytes
Liu, Y., Guan, H., Beckett, T. L., Juliano, M. A., Juliano, L., Song, E. S., Chow, K. M., Murphy, M. P., & Hersh, L. B. (2007) · Peptides · doi:10.1016/j.peptides.2007.09.015 · Cited by 24
“These include apolipoprotein E (apoE), α2-macroglobulin (α2M), and the low-density lipoprotein receptorrelated protein (LRP) [6,8,10,40,46].”
Backgroundde Almeida, S. M., Ribeiro, C. E., Rotta, I., Piovesan, M., Tang, B., Vaida, F., Raboni, S. M., Letendre, S. L., Potter, M., Fernandes, M. S. B., et al. (2017) · Journal of NeuroVirology · doi:10.1007/s13365-017-0591-3 · Cited by 24
“However, the degradation of free Aβ in brain interstitial fluid has been reported to be insignificant (Shibata et al. 2000).”
BackgroundKwak, D. E., Ko, T., Koh, H. S., Ji, Y. W., Shin, J., Kim, K., Kim, H. Y., Lee, H. K., & Kim, Y. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227618 · Cited by 25
Immunotherapy for Alzheimer's disease and other dementias
Boche, D., Nicoll, J. A. R., & Weller, R. O. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000191513.60368.a7 · Cited by 24
“Amyloid-$ is degraded by enzymes such as neprilysin and insulin degrading enzyme in the brain parenchyma and is absorbed directly into the blood by a mechanism mediated by lowdensity lipoprotein receptor-related-protein-1 (LRP-1).(10,11) These pathways for elimination of amyloid-$ appear to fail in older mice and prob…”
BackgroundN-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
Rostagno, A. A., Cabrera, E., Lashley, T., & Ghiso, J. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00303-3 · Cited by 24
Self-citationGrimmer, T., Goldhardt, O., Guo, L., Yousefi, B. H., Förster, S., Drzezga, A. E., Sorg, C., Alexopoulos, P., Förstl, H., Kurz, A., et al. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.01.016 · Cited by 26
“LRP-1 may play an important role in AD, since in mice inhibition of LRP-1 by the inhibitor RAP (receptor associated protein) or by LRP-1 antibodies leads to substantial reduction in amyloid clearance (Shibata et al., 2000; Williams et al., 1992).”
BackgroundInfluentialCopper Transporters? Glutathione Reactivity of Products of Cu–Aβ Digestion by Neprilysin
Stefaniak, E., Płonka, D., Szczerba, P., Wezynfeld, N. E., & Bal, W. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c00427 · Cited by 24
Clearance of Amyloid Beta Plaques from Brain of Alzheimeric Rats by Lavandula angustifolia
Soheili, M., Rezaei–Tavirani, M., & Salami, M. (2012) · Neuroscience & Medicine · doi:10.4236/nm.2012.34044 · Cited by 25
“to-blood Aβ efflux transport across the blood-brain barrier and Aβ degradation by protease have been reported as cerebral Aβ clearance mechanisms [23,24].”
BackgroundAβ immunization: Moving Aβ peptide from brain to blood
Lee, V. M. ‐. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171311798 · Cited by 25
Ding, Y., Palecek, S. P., & Shusta, E. V. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00580-2 · Cited by 23
“Both Aβ monomer and APOE-Aβ complexes can be cleared at the BBB [23, 38, 75–78] (Fig.”
BackgroundAmyloid-β Peptide-specific DARPins as a Novel Class of Potential Therapeutics for Alzheimer Disease
Hanenberg, M., McAfoose, J., Kulic, L., Welt, T., Wirth, F., Parizek, P., Strobel, L., Cattepoel, S., Späni, C. B., Derungs, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564013 · Cited by 26
Zhao, H., Sun, M., Zhang, Y., Kong, W., Fan, L., Wang, K., Xu, Q., Chen, B., Dong, J., Shi, Y., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0516 · Cited by 24
“In this process, wastes removal from the perivascular spaces rely primarily on microglia, pericytes and perivascular phagocytes [43-45].”
Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE ε4 Carriers
Duits, F. H., Kester, M. I., Scheffer, P. G., Blankenstein, M. A., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122227 · Cited by 23
“the brain [29, 30].”
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






